Melanotan I 10mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Melanotan I is studied primarily in melanocortin-1 receptor signalling and eumelanin synthesis models. The two substitutions that define it, norleucine at position 4 and D-phenylalanine at position 7, confer resistance to enzymatic degradation while preserving MC1R affinity. Because it lacks meaningful MC3 and MC4 activity, it is the more selective of the two Melanotan research materials and is often used as the control arm when investigators need to separate MC1R-mediated pigmentation effects from the broader melanocortin activity of Melanotan II.
Frequently Bought Together
Melanotan I 10mg
10mg
$39 USD
Bundle & Save
$64 USD
Save $4 USD
$159 USD
Save $14 USD
$189 USD
Save $29 USD
$224 USD
Save $44 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Oxytocin's Vital Role in Social and Relationship Bonds
Oxytocin, known as the love hormone, supports social connections through release during touch, trust, and intimacy. Research indicates it aids trust, empathy, and bonding in romantic, parental, and friendly relationships, though effects depend on context and individual factors. This peptide also interacts with stress systems to promote emotional regulation and well-being.
Atosiban Serves as Maintenance Therapy for Preterm Labor
Atosiban, an oxytocin-receptor antagonist marketed in China in 2006, offers maintenance treatment to manage preterm labor risks after initial tocolysis. Clinical trials show it delays delivery better than placebo in some cases and has fewer side effects than beta-2 agonists. Studies highlight its safety and role in reducing recurrent preterm labor episodes.